Evidence map›Paper›PMID 38524665›Full record

ArticleCase reports in gastrointestinal medicine2024

Low Dose Pregabalin Improves Gastrointestinal Symptoms of Crohn's Disease.

Antonio Maria D'Onofrio, Federica Di Vincenzo, Gaspare Filippo Ferrajoli, Franco Scaldaferri, Giovanni Camardese

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in gastrointestinal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 1 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Antonio Maria D'OnofrioDepartment of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Rome 00168, Italy.ORCID https://orcid.org/0009-0007-6807-5796
Federica Di VincenzoUOS Malattie Infiammatorie Croniche Intestinali, CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy.ORCID https://orcid.org/0000-0002-5347-7641
Gaspare Filippo FerrajoliDepartment of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Rome 00168, Italy.ORCID https://orcid.org/0009-0005-7134-7524
Franco ScaldaferriUOS Malattie Infiammatorie Croniche Intestinali, CEMAD Digestive Diseases Center, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, Rome 00168, Italy.ORCID https://orcid.org/0000-0001-8334-7541
Giovanni CamardeseDepartment of Neuroscience, Section of Psychiatry, Università Cattolica del Sacro Cuore, Rome 00168, Italy.ORCID https://orcid.org/0000-0002-8139-9230
Università Cattolica del Sacro Cuore · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are lifelong conditions with no definite cure. Several studies demonstrated that patients with IBD more frequently experience symptoms of common mental disorders, such as anxiety and depression, because of bidirectional communication through the gut-brain axis and the chronicity of symptoms, as well as because of impaired quality of life and reduced social functioning. However, psychological conditions of affected patients are often underestimated and not fully considered. Herein, we present the case of a 37-year-old woman with Crohn's disease and a mild depressive condition, characterized by anxious distress, tachycardia, tachypnea, tremors, sweating, avoidant behaviors, and intestinal somatizations (diarrhea), who was treated with Pregabalin upon indication of the referring psychiatrist. Following the beginning of the treatment, the patient rapidly reported an improvement in the overall clinical symptoms as well as a better management of psychic and physical anxiety with a marked reduction in diarrheal discharges under stress at work. After 6 months of Pregabalin therapy, we additionally observed an improvement in Crohn's disease activity, both clinically, in the laboratory, and endoscopically. Our case showed that patients with Crohn's disease and anxiety problems may benefit from low-dose Pregabalin medication to improve both their mental and physical condition.

Identifiers

PMID38524665
PMCPMC10959577
OpenAlexW4392855554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.